Furthermore, it is necessary to assess the levels of sPD-1/sPD-L1 in MS patients and to determine whether they play a proinflammatory or anti-inflammatory role in MS and whether they may cause tolerance or resistance of T cells to the PD-1 pathway. Here, PDCD1 is linked to myeloid sarcoma.